Loss of olfactomedin 4 (OLFM4) gene expression is associated with the progression of human prostate cancer, but its role and the molecular mechanisms involved in this process have not been completely understood. In this study, we found that Olfm4-knockout mice developed prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Importantly, we found that the hedgehogsignaling pathway was significantly upregulated in the Olfm4-knockout mouse model. We also found that restoration of OLFM4 in human prostate-cancer cells that lack OLFM4 expression significantly downregulated hedgehog signaling-pathway component expression. Furthermore, we demonstrated that the OLFM4 protein interacts with sonic hedgehog protein, as well as significantly inhibits GLI-reporter activity. Bioinformatic and immunohistochemistry analyses revealed that decreased OLFM4 and increased SHH expression was significantly associated with advanced human prostate cancer. Thus, olfactomedin 4 appears to play a critical role in regulating progression of prostate cancer, and has potential as a new biomarker for prostate cancer.
. Frequent genetic deletion of the OLFM4 gene has been found in advanced prostate cancer 16 and squamous cell carcinomas 17 . Gene-expression data have revealed downregulation of the OLFM4 gene in prostate cancer, colon cancer, and leukemia, whereas OLFM4 expression was found to be upregulated in gastric cancer and pancreatic cancer. These divergent results may be due to tissue-and cell-specific factors, as well as inflammation status and tumor grade 18 . In this study, we examined the potential functions of the Olfm4 gene in murine prostate tissues by analyzing an Olfm4-knockout mouse model, and found that loss of Olfm4 leads to neoplastic progression in the mouse prostate, as well as tumor formation in the lung, liver, and pancreas. We further explored the possible molecular mechanisms underlying prostate neoplastic progression in Olfm4-knockout mice and found that Olfm4 negatively regulates the hedgehog-signaling pathway in mouse prostate. Bioinformatic analyses revealed that expression of OLFM4 was significantly downregulated in advanced human prostate cancer. Our findings suggest that loss of olfactomedin 4 upregulates the hedgehog-signaling pathway and promotes progression of prostatic neoplasms.
Results
Olfm4-knockout mice sporadically develop prostatic epithelial lesions and other organ tumors. To investigate the functions of the Olfm4 gene in murine prostate, we analyzed genomic DNA, mRNA, and protein in the prostate tissue of wild-type (Olfm4+ /+ ) and Olfm4-knockout (Olfm4− /− ) mice. We verified that prostate tissues from wild-type mice expressed Olfm4 genomic DNA, Olfm4 mRNA, and Olfm4 protein, whereas those from Olfm4-knockout mice did not ( Supplementary Fig. S1 ). Histopathological analysis demonstrated normal prostate tissue morphology for wild-type mice at early ages, and none developed prostatic intraepithelial neoplasia by 24 months of age. However, Olfm4-knockout mice sporadically developed prostatic epithelial lesions in an age-dependent manner. Prostatic epithelial hyperplasia was seen at 3-6 months of age, prostatic intraepithelial neoplasia was observed at 10-12 months of age, and higher-grade prostate intraepithelial neoplasia was observed at 18-24 months of age in Olfm4-knockout mice (Supplementary Table S1 ). Lower-grade prostatic epithelial hyperplasia (LG-PIN) was observed in the anterior prostate (AP) and dorsal-lateral prostate (DLP) of Olfm4-knockout mice at 18 months (Fig. 1a) . Higher-grade prostatic intraepithelial neoplasia (HG-PIN), as well as inflammatory cells, was observed in the DLP of Olfm4-knockout mice at 20 months of age (Fig. 1b , upper panels). Microinvasion in tumor was observed in the DLP tissue of Olfm4-knockout mice at 23 months of age (Fig. 1b, lower panels) .
Histological and immunohistochemical evaluation of DLP tissue from 20-month-old Olfm4-knockout mice revealed that the tumor type that developed in the Olfm4-knockout mice was androgen receptor (AR)-positive prostatic adenocarcinoma (Fig. 1c) . The frequency of prostatic intraepithelial neoplasia lesions was increased in Olfm4+ /− and Olfm4− /− mice compared with Olfm4+ /+ mice at ages 13-24 months (Fig. 1d ). In addition, we found a generally higher incidence of lung, liver, and pancreatic tumors in Olfm4+ /− and Olfm4− /− mice compared with Olfm4+ /+ mice at 13-24 months of age ( Fig. 1e and Supplementary Fig. S2 ). These results suggest that Olfm4 plays a pivotal tumor-suppressor role in murine prostate and other organs.
Olfm4 deficiency is associated with proliferation of prostate epithelial cells. To determine whether Olfm4 affects proliferation or apoptosis of prostatic epithelial cells in Olfm4-knockout mice, we performed Ki67 immunohistochemical staining and terminal deoxynucleotidyltransferase-mediated nick end labeling (TUNEL) assays. Ki67-positive cells were detected in prostatic epithelial lesions in the DLP of 12-month-old Olfm4-knockout mice (Fig. 2a) . The percent of Ki67-positive cells was significantly increased in the DLP of Olfm4-knockout mice compared with age-matched wild-type mice at different ages (Fig. 2b) . However, no difference in apoptosis was observed when TUNEL assay and anti-caspase 3 Western blot results for prostate tissues of Olfm4-knockout mice were compared with those from wild-type mice (Fig. 2c-e) . These results suggest that loss of Olfm4 is associated with proliferation of murine prostate epithelial cells.
Olfm4-knockout mouse prostate demonstrates increased levels of hedgehog signalingpathway and target genes. Gene-microarray data analysis indicated that the hedgehog-signaling pathway was significantly changed in Olfm4-knockout mouse prostate (Fig. 3a) . The mRNA expression of the hedgehog signaling-pathway genes Shh and Ptch1, Shh's direct-target genes Ccnd1, Ccnd2, Foxc2, and Prdm1, and Shh's indirect-target genes, including the stem-cell signaling network and stem-cell markers Cd44, Nes, Wnt5a, Hes1, Pdgfra, and Fst, were significantly upregulated in prostate tissues from both or either 3-month-old and 15-month-old Olfm4-knockout mice compared with those from wild-type mice (Fig. 3b) . Using qRT-PCR, we further found an approximately 2-fold or higher increase in the expression of Shh, Ptch1, Gli1, and Gli2 in prostate tissues from 3-month-old Olfm4-knockout mouse compared with those from wild-type mice (Fig. 3c) . The increased expression of hedgehog signaling-pathway component genes in the prostate of Olfm4-knockout mice compared with wild-type mouse prostate was also verified at the protein level (Fig. 3d) . Interestingly, we found that some hedgehog-signaling target genes (including the prostate stem/progenitor cell marker gene Cd44, as well as some epithelial-to-mesenchymal [EMT] marker genes, including Zeb2, Foxc2, Vim, Fn1, and Cdh2) were significantly upregulated in prostate tissues from 15-month-old Olfm4-knockout mice compared with those from wild-type mice (Fig. 3e,f) . In contrast, the cytokeratin genes Krt25, Krt4, and Krt79 were found to be significantly downregulated in prostate tissues from 15-month-old Olfm4-knockout mice compared with those from wild-type mice (Fig. 3e) . These results suggest that loss of Olfm4 leads to enhanced hedgehog signaling-pathway and pathway-target gene expression.
OLFM4 downregulates hedgehog signaling-pathway components in human prostate-cancer cell lines. We have previously verified that human metastatic prostate-cancer cells lack OLFM4 expression 12 . We next studied hedgehog signaling-pathway components in human prostate-cancer cell lines stably expressing the OLFM4 gene. We found that expression of the hedgehog-signaling components SHH, PTCH1, and GLI1 was reduced between 30-70% in OLFM4-expressing prostate-cancer cells compared with control vector-transfected cells (Fig. 4a) . Protein expression of the hedgehog signaling-pathway components SHH, PTCH1, GLI1, and GLI2 was also generally reduced in OLFM4-expressing prostate-cancer cells compared with control vector-transfected cells (Fig. 4b ). In addition, AR-positive, androgen-sensitive VCaP prostate-cancer cells transiently overexpressing OLFM4 displayed reduced expression of SHH and GLI at the mRNA level but not the protein level ( Supplementary Fig. S3 ). The expression of PTCH1 was not changed may be due to the specific cellular context ( Supplementary Fig.  S3 ). Collectively, these results suggest that the expression of OLFM4 in human prostate-cancer cell lines that normally lack OLFM4 expression inhibits the hedgehog-signaling pathway.
OLFM4 protein directly interacts with sonic hedgehog (SHH) protein, reduces level of SHH protein in the culture media of PC-3 cells, and inhibits GLI-reporter activity. To investigate whether OLFM4 protein directly or indirectly affects the hedgehog-signaling pathway, we examined OLFM4 and SHH localization in OLFM4-expressing PC-3 cells. The OLFM4 and SHH proteins were observed to be colocalized in these cells (Fig. 5a ). The physical interaction between OLFM4 and SHH was also detected in PC-3 cells stably expressing OLFM4 or OLFM4-N (a truncated deletion of OLFM4) using coimmunoprecipitation analysis (Fig. 5b) . SHH protein secretion was significantly reduced in the conditioned culture media of PC-3 OLFM4-expressing cell clones compared with PC-3 vector control-transfected cell clones (Fig. 5c ). These results suggest that OLFM4 downregulated both cellular and secreted levels of SHH protein. To study whether OLFM4 protein directly inhibits hedgehog signaling-pathway activity, we performed GLI-reporter activity assays with human prostate-cancer cells. We found dose-dependent inhibitory effects when OLFM4 plasmid was cotransfected with GLI-reporter plasmid in PC-3 ( Fig. 6a ) and 22RV1 cells (Fig. 6b) , as well as in 293T cells (Supplementary Fig. S4a ). Exogenous OLFM4 protein significantly inhibited GLI-reporter activity in 293T cells (Supplementary Fig. S4b ). Further, OLFM4 protein and cyclopamine synergistically inhibited GLI-reporter activity in 293T cells (Supplementary Fig. S4b ). These findings suggest that OLFM4 protein is a natural antagonist of the hedgehog-signaling pathway.
Expression of OLFM4, SHH, and hedgehog signaling-pathway target genes in human prostate-cancer specimens reflects expression patterns seen in prostate tissue from Olfm4-knockout mice. Given our results observed in Olfm4-knockout mice and human prostate-cancer cells, we sought to analyze the expression of OLFM4, SHH, and hedgehog signaling-pathway target genes in the GSE35988 19 and GDS2545 (GEO profiles) datasets. OLFM4 was significantly downregulated in metastatic tumor tissue when compared with normal prostate tissue, whereas SHH was significantly upregulated in metastatic tumor tissue when compared with normal prostate tissue ( Fig. 7a and Supplementary , and PDGFRA 22 were upregulated in human primary and metastatic tumors when compared with normal prostate tissue ( Supplementary Fig. S5, lower row ). An indirect regulator gene, WNT5A 23 , was upregulated in metastatic tumors when compared with normal prostate tissue ( Supplementary Fig. S5 , lower row). WNT5A mediates the protein kinase C pathway to promote invasion and metastasis 24 , while the PDGFRA gene (which encodes platelet-derived growth factor receptor alpha) upregulates the ERK signaling pathway in basal cell carcinoma 22 . The expression of OLFM4 and SHH proteins was examined in prostate-cancer tissue-array samples using immunohistochemistry. We detected positive OLFM4 staining, but not SHH staining, in Gleason score 4-7 prostate-cancer specimens, while OLFM4 staining was reduced or lost and SHH staining was increased in Gleason scores 8-10 prostate-cancer specimens (Fig. 7b and Supplementary Table S2 ). The percentage of OLFM4-and SHH-positive prostate-cancer specimens was 80% and 40% in Gleason scores 4-7, and 22% and 57% in Gleason scores 8-10, respectively (Fig. 7c) . Loss of protein expression of OLFM4 and increased expression of SHH were significantly associated with high grade of prostate cancer (Supplementary Table S2 ). These results suggest that reduced or lost OLFM4 gene expression and increased SHH gene expression are associated with human prostate neoplastic progression.
Discussion
OLFM4 is located on chromosome 13q14.3 11 , which is frequently deleted in many human cancers, including prostate cancer. We have found previously that deletion of the OLFM4 gene is associated with the progression of human prostate cancer 16 . Further, our functional studies of OLFM4 in human prostate-cancer cells have demonstrated that restoration of OLFM4 expression in the metastatic prostate-cancer cell line PC-3 significantly inhibited cancer-cell growth, invasion, and metastasis 12 . Our previous findings have strongly suggested that OLFM4 plays a critical role in regulating progression of human prostate cancer.
Olfm4-knockout mice have previously been shown to demonstrate normal early development, and Olfm4 does not appear to be essential for normal development and growth in mice 25 . Because Olfm4 is normally expressed in the mouse prostate, we used the Olfm4-knockout mouse model to examine the relationship between Olfm4 deficiency and prostate neoplastic progression. In this study, we found that approximately 70% of Olfm4-knockout mice developed prostatic epithelial lesions. The frequency of tumor formation in the liver, lung, and pancreas was also significantly increased in older Olfm4-knockout mice. Thus, the Olfm4 gene seems to serve as a tumor suppressor in the progression of prostate cancer and other tumors. , and GLI1 in prostate-cancer cell clones. Data represent the mean (± SD) percent expression in OLFM4-GFP tag-expressing cell clones compared with vector-GFP tag-expressing cell clones (value set at 100%) (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. The significance of differences between experimental groups was determined by the Student's t-test. (b) Western-blot analysis of protein expression for OLFM4, SHH, PTCH1, GLI1, and GLI2 in prostate-cancer cell clones. β -actin was used as a loading control. Gene-expression profile studies of Olfm4-knockout mouse prostate tissue at 3 and 15 months of age demonstrated that loss of Olfm4 significantly altered gene-expression levels of hedgehog signaling-pathway genes and target genes. Given this gene-expression profile, we explored a potential novel function of Olfm4-that of modulating the hedgehog-signaling pathway.
Overexpression of hedgehog has been reported to initiate prostate stem/progenitor cell transformation in normal murine prostate tissue and to cause lesions with characteristic prostatic intraepithelial neoplasia or/and prostatic cancer in murine prostate 10 . Furthermore, activation of the hedgehog-signaling pathway by using stable transfection of GLI in rodent prostate-cancer lines has demonstrated that hedgehog-pathway activity upregulates EMT and determines metastatic potential 4 . Interestingly, we found that Olfm4-knockout murine prostate displayed neoplastic progression and elevated expression of hedgehog signaling-pathway component and target genes, as well as EMT marker genes. We also obtained more evidence of OLFM4's ability to inhibit hedgehog-signaling activity in human prostate-cancer cell lines. It has been previously shown that overexpression of hedgehog ligands in human prostate-cancer cell lines promotes growth, while a hedgehog signaling-specific inhibitor significantly reduces growth in a human prostate-cancer cell xenograft model 4 . In this study, we observed that restoration of OLFM4 in human metastatic prostate-cancer cell lines lacking expression of OLFM4 inhibited hedgehog-signaling activity. Based on our new findings, we postulate that OLFM4 protein binds to the SHH protein, blocks the binding of SHH to its receptor, PTCH1, and therefore inhibits hedgehog signaling-pathway activities (Fig. 7d) . Conversely, loss of OLFM4 protein would increase hedgehog signaling-pathway activity and cross-talk with other pathways that mediate hedgehog-signaling pathway activities.
Taken together, our findings suggest that OLFM4 plays a critical role in regulating progression of prostate cancer and might be useful as a novel candidate biomarker for improving diagnostic/prognostic accuracy and as a likely target for therapeutic approaches to prostate cancer. 
Methods
Mouse procedures. All animal experiments were approved by the Animal Care and Use Committee of the National Heart, Lung, and Blood Institute (NHLBI). Animal care was performed in accordance with relevant institutional and national guidelines and regulations in the animal facilities of the National Institutes of Health (NIH). Generation of Olfm4-knockout mice has been described previously 25 . The Olfm4-knockout mice were maintained by crossing Olfm4(+ /− ) mice. The animals were genotyped using PCR with primers as described previously 25 . The genetic background of these mice was 50% 129/SV and 50% National Institutes of Health Black Swiss.
Mouse tissue collection, histopathological analysis, and immunohistochemistry. Prostate microdissection was performed following a previously described procedure 26 ; other tissues were also harvested at the time of sacrifice. Histological and immunohistochemical analyses were performed on formalin-fixed paraffin sections as previously described 16 . Histological analysis was performed on HE-stained tissue slides on a blinded basis by Dr. Victoria Hoffmann, DVM, DACVP (Division of Veterinary Resources/NIH), Dr. Jaime Rodriguez-Canales MD (a pathologist in the Laboratory of Pathology, National Cancer Institute, NIH), and one of the authors (Dr. H. Li, MD, PhD).
LG-PIN (I-II) and HG-PIN (III-IV) were identified according to recommendations for scoring mouse prostate-cancer models that have been published previously 26, 27 . Immunohistochemical staining was performed with the following antibodies: anti-AR (PG-21; Millipore); anti-p63 (Santa Cruz Biotechnology, Inc.); anti-synaptophysin SY38 (Abcam); and anti-Ki67 antigen (polyclonal, NovoCastra Laboratories). Secondary antibodies, Super Sensitive MultiLink, and Super Sensitive Label were purchased from BioGenex. Dark brown color was developed with chromagen (BioGenex) and counterstained with hematoxylin. The Ki67-staining samples were evaluated by counting a total of thousands cells in 5 areas of each sample.
All images were acquired using an Olympus BX51 microscope (Olympus) and Qimaging Camera with Q Capture pro software (Qimaging). Images were acquired using the × 60 Uplan Apo objective (1.42 oil), then imported into Adobe Photoshop for presentation.
Immunofluorescent staining. Immunofluorescent staining of human prostate-cancer cells was performed with anti-V5 (Invitrogen) or anti-SHH (Millipore) antibodies, and immunofluorescent . Bar graph represents the relative GLIreporter activity that was normalized by using cotransfection with Renilla luciferase and detected using the dual-luciferase reporter assay system. The mean percent was obtained by comparing activity in triplicate transfections for each experimental condition to the activity for the SHH-N-treated sample (number 2; value set at 100%). SHH-N protein (100 nM) was added 48 h after transfection, and GLI-reporter activity was measured 24 h later. Carry plasmid indicates plasmid carried empty vector. Data represent the mean ± SD of triplicate experiments. *P < 0.05. The significance of differences between experimental groups was determined by ANOVA. Shadow triangle indicates dose of OLFM4 cDNA plasmid. staining of mouse prostate tissues was performed with an anti-OLFM4 polyclonal antibody 28 , followed by secondary antibody (Alexa Fluor 488-conjugated goat anti-rabbit or anti-mouse or Alexa Fluor 596-conjugated goat anti-rabbit or anti-mouse; all from Invitrogen). Nuclei were counterstained with DAPI (4′ ,6-diamidino-2-phenylindole dihydrochloride).
All images were acquired using an Olympus BX51 microscope and Qimaging Camera with Q Capture pro software. Images were acquired using the × 60 Uplan Apo objective (1.42 oil), then imported into Adobe Photoshop for presentation.
Gene-microarray analysis. Total RNA was purified from whole prostate tissue from wild-type and Olfm4-knockout mice at 3 and 15 months of age using the RNeasy Plus Mini Kit (Qiagen). cDNA microarray analyses were performed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Core Facility at the NIH using Affymetrix Mouse Genome 430 2.0 Array GeneChips (Affymetrix). Five biological replications were used for the wild-type or Olfm4-knockout prostate RNA extracted from 5 individual mice. The microarray signals were analyzed using the Affymetrix RMA algorithm. Analysis of variance results, false discovery rate reports, and heatmaps were generated using Partek Genomic software 6.5 (Partek). Enrichment analyses of GO categories, which include disease markers, as well as biological process and pathway analyses, were performed using MetaCore web-access software (http://www.genego.com).
Genomic DNA PCR and qRT-PCR analysis. qRT-PCR was conducted as previously described 12 . The TaqMan real-time PCR primers and probes were purchased from Applied Biosystems. Relative expression was calculated using Δ Δ Ct methods. Genomic DNA and total RNA were extracted from mouse prostate and genomic DNA PCR 25 and semi-quantitative RT-PCR 12 were performed as previously described.
Western-blot analysis. Samples were separated using 4-12% polyacrylamide gel electrophoresis, transferred to polyvinyldiene fluoride membrane, and hybridized with anti-OLFM4 (Sino Biological Inc.), anti-SHH, PTCH1, GLI1, or GLI2 or anti-Shh, Ptch1, Gli1, or Gli2 (Abcam), anti-β -actin (Santa Cruz Biotechnology, Inc.), or anti-caspase 3 (Cell Signaling Technology, Inc.) antibodies overnight at 4 °C. The membranes were then incubated with secondary antibody and signal developed with Amersham ECL Western-blotting detection reagents (GE Healthcare).
Generation of stably expressing OLFM4-GFP prostate-cancer cell clones. PC-3, 22RV1, and DU145 human prostate-cancer cell lines were purchased from ATCC. We have previously verified that human metastatic prostate-cancer cells lack OLFM4 expression 12 . The construction of vector-V5 tag, OLFM4-V5 tag, and truncated mutant OLFM4-Flag tag plasmids and their stable expression in plasmid cell clones have been previously described 12, 16 . PC-3V (vector-transfected control) clone, PC-3W (full-length OLFM4-V5 tag-expressing) clone, and PC-3N (expressing a truncated mutant of OLFM4-Flag tag in which the olfactomedin domain is missing) clone cells were cultured in RPMI 1640 media containing 10% fetal bovine serum (FBS) until 90% confluent 16, 28 . The pCMV-6-AC-GFP tag-vector and pCMV-6-OLFM4-GFP tag plasmids were purchased from Origene. Stably expressing OLFM4-green fluorescent protein (GFP) tag-expressing prostate-cancer cell clones (O) or vector-GFP tag-transfected control prostate-cancer cell clones (V) were established following previously described protocols 12, 16 . Coimmunoprecipitation assays. For coimmunoprecipitation assays, PC-3 cells were harvested and lysed in immunoprecipitation lysis buffer 29 . Culture media were harvested from 48-h cell cultures in T75 flasks. Cell lysates (500 μ g in 0.5 mL) were mixed with 2 μ g of normal IgG or antibody to Flag (Sigma-Aldrich) or V5 (Invitrogen), then incubated for 3 h at 4 °C. Following this incubation, 100 μ L of rec-Protein G-Sepharose 4B conjugate (Invitrogen) was added and incubated with mixing overnight at 4 °C. After centrifugation at 3,000 × g for 1 min, supernatants were aspirated and discarded. Pellets were washed in lysis buffer 3 times for 15 min. Sample buffer (30 μ L) was added to the agarose pellets, which were then boiled for 10 min. Samples were then subjected to Western-blot analysis.
Generation of transiently overexpressing
GLI-reporter assays. The Cignal reporter and Cignal lenti reporter assay kits were purchased from Qiagen. Transient transfection of 293T cells (ATCC) or prostate-cancer cells with Cignal lentiviral particles or GLI-reporter plasmids was performed following the manufacturer's instructions. Briefly, for Cignal lenti reporter transfection, 1 × 10 4 cells/well of 293T cells were plated onto 96-well plates and transfected with Cignal lentiviral particles following the manufacturer's instructions. After 48 h, the cells were treated with different concentrations of OLFM4 protein (Sino Biological Inc.) (1.5-6.0 μ M) and/or SHH-N (R&D Systems) (200 nM) in Opti-MEM containing 0.5% FBS for 24 h in 96-well plates. In some assays, cyclopamine (1 μ M) was included in the culture media. For transient cotransfection of GLI-reporter plasmid and vector control plasmid, OLFM4 cDNA plasmid, and/or carry plasmids (empty vector only), 2 × 10 6 cells/well of 293T cells were plated onto 6-well plates or 1 × 10 5 cells/well of PC-3 or 22RV1 cells were plated onto 24-well plates. The cells were transfected with GLI-reporter plasmids combined with OLFM4 cDNA plasmids or control vector plasmids and/or carry plasmids. After 48 h, the cells were treated with 100 nM SHH-N in Opti-MEM containing 0.5% FBS for 24 h in 96-well plates. GLI-reporter activity was detected using a dual-luciferase reporter assay system (Promega).
SHH ELISA assays. SHH ELISA was performed using the ab100639-Sonic Hedgehog Human ELISA Kit (Abcam). Briefly, cell-culture media samples were harvested from 3 individual wells of 12-well plates after culturing for 6, 18, 24, 30, 42, or 54 h and diluted 10-fold by using 1× assay diluent B, then incubated overnight at 4 °C in the ELISA plate. The OD values were measured at 450 nm with a 1420 Multilabel Counter (Perkin Elmer Inc.).
TUNEL assays. TUNEL assays were performed according to the instructions for the In Situ Cell Death Detection Kit (Roche). The proportion of positive cells was determined by counting a total of thousands cells in 5 areas of each sample.
Human prostate cancer tissue array and immunohistochemistry. Prostate cancer tissue arrays were purchased from US Biomax (catalogue number PR803). The immunohistochemical staining with OLFM4 antibody and SHH antibody (ab53281, abcam) and quantitation of immunohistochemistry staining results was performed as previously described 16 .
Statistical analysis. Statistical analyses were performed using the Student's t-test, ANOVA, log-rank test, or the Mann-Whitney U test. P-values < 0.05 were considered statistically significant.
Accession website. The GEO submission number for the microarray data discussed in this publication is GSE39989. The GEO database is available at http://www.ncbi.nlm.nih.gov/geo.
